

## Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers

**Xintela starts its second clinical study (Phase I/IIa) with XSTEM® for the treatment of difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin  $\alpha 10\beta 1$ -selected mesenchymal stem cells, is developed and manufactured by Xintela.**

The recruitment of patients for the Phase I/IIa study for the treatment of difficult-to-heal venous leg ulcers, which is carried out at Linköping University Hospital, has now begun. Twelve patients with difficult-to-heal venous leg ulcers will receive a treatment of XSTEM or placebo applied to the wound and will then be followed up weekly for 10 weeks and after 6 months. The primary goal of the study is to show that the treatment is safe but also that XSTEM has a positive effect on wound healing. Early safety and efficacy data are expected before the end of 2022.

"We are very excited to start the second clinical study with our stem cell product XSTEM. Our previous preclinical studies have shown that XSTEM has an excellent wound healing effect in a preclinical model and has the potential to become a pioneering treatment for difficult-to-heal leg ulcers and other skin defects," says Xintela's CEO Evy Lundgren-Åkerlund.

### Contacts

#### **Xintela AB (publ)**

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: [evy@xintela.se](mailto:evy@xintela.se)

Medicon Village

223 81 Lund, Sweden

[www.xintela.se](http://www.xintela.se)

## About Xintela

---

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin  $\alpha 10\beta 1$  which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin  $\alpha 10\beta 1$  (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

## Attachments

---

[Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers](#)